epiH Search


Korean Journal of Epidemiology 1990;12(1): 38-43.
레세르핀과 유방암 발생과의 관련성
Association between use of reserpine and breast cancer
Kwang Ho Meng
Reserpine was being widely used as a well-established, beneficial treatment for hypertension, when three studies, published in 1974 in the same issue of the Lancet, suggested that reserpine users, compared with non users, had a threefold to fourfold increased risk of developing breast cancer. These results were subsequently contradicted by the results of nine other studies, published between 1975 and 1980. In a recent review of all those studies, the initial causal association was deemed erroneous, although the reasons for the falsely positive results were not identified. Recently, however, one study done by Horwitz and his colleagues in Yale University claimed that the false association might have been produced by a phenomenon called exclusion bias that were probably happened because patients with cardiovascular disease were rejected as possible controls in the original reserpine-breast cancer case-control study. This paper summarizes the results of those studies resulted in positive and negative associations between the use of reserpine and breast cancer, and reviews the methodological variations of the studies.


Browse all articles >

Editorial Office
Graduate School of Cancer Science and Policy, National Cancer Center
323 Ilsan-ro, Ilsandong-gu, Goyang 10408, Korea
TEL: +82-2-745-0662   FAX: +82-2-764-8328    E-mail: enh0662@gmail.com

Copyright © 2020 by Korean Society of Epidemiology. All rights reserved.

Developed in M2community

Close layer
prev next